The composition and use of Oral contraceptives (OCs) have Changed since their
cardiovascular side-effects were established 20 years ago. This report describes the risk of …

The newer progestogens gestodene, desogestrel and norgestimate were developed in an
attempt to produce agents with more selective progestational activity that would improve …

This review details the characteristic features of three new progestogens which soon will be
available in low-combination oral contraceptive agents in the United States. Available data …

Ethinylestradiol and drospirenone combined oral contraceptive formulations have been
marketed for> 20 years. Drospirenone has antimineralocorticoid and anti-androgenic effects …

Lipoprotein metabolism is involved in atherogenesis. Female sex-hormones have
substantial effects on both lipoprotein metabolism and the vessel wall. Cholesterol, one of …

In October 1995 the United Kingdom Committee on Safety of Medicines stated in a letter to
all UK physicians and pharmacists that women taking oral contraceptives containing …

The use of 17α-ethynyl estrogens in contraceptive formulations originated by accident. The
first 19-norprogestins to be used for contraceptive purposes (norethindrone and …

The purpose of the present report is to summarize the most important pharmacokinetic
features of the new progestogens. In addition, the question of whether or not gestodene, in …

In October, 1995, the United Kingdom Committee on Safety of Medicines recommended that
women should use oral contraceptives containing desogestrel or gestodene only if prepared …

Gestodene, one of three new gonane progestins, is the most potent on a per weight basis in
regard to progestational effects and has little or no estrogenic effect. In in vivo animal …